Subscribe

What are you looking for?

Main Menu

復星醫藥子公司藥友製藥與輝瑞簽訂許可協議 前者可獲12億首付款

Future Wealths
Future Wealths
9 12 月, 2025
One Min Read
4 Views
0 Comments
復星醫藥（2196）宣布，其控股子公司藥友製藥與輝瑞（美：PFE）簽訂許可協議，授權輝瑞在全球範圍內開發、製造及商業化口服小分子GLP‑1受體激動劑YP05002及相關產品，許可領域包括所有人類及動物適應症的治療、診斷及預防。

原文: https://finance.mingpao.com/fin/instantf/20251209/1765283690220/%e5%be%a9%e6%98%9f%e9%86%ab%e8%97%a5%e5%ad%90%e5%85%ac%e5%8f%b8%e8%97%a5%e5%8f%8b%e8%a3%bd%e8%97%a5%e8%88%87%e8%bc%9d%e7%91%9e%e7%b0%bd%e8%a8%82%e8%a8%b1%e5%8f%af%e5%8d%94%e8%ad%b0-%e5%89%8d%e8%80%85%e5%8f%af%e7%8d%b212%e5%84%84%e9%a6%96%e4%bb%98%e6%ac%be

Last Update: 9 12 月, 2025

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept